Page 5 - Marek Ciszewski News Today

About Actuate Therapeutics Actuate Therapeutics, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases. For additional information, please visit the companys website at http://www.actuatetherapeutics.com.   About Lantern Pharma Lantern Pharma (Nasdaq: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR ® A.I. platform and machine learning to...

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights - RADR® A.I. platform surpasses 4.6 billion datapoints curated for oncology drug development across a wide a range of tumors and drug classes - Phase 2 clinical trial for non-smokers with NSCLC (Non-Small Cell Lung Cancer) utilizing LP-300 in combination with chemotherapy scheduled to begin during third quarter of 2021 - Expanded potential indications for LP-184 to include ATRT pediatric brain cancers - Init...

Share this article DALLAS, April 26, 2021 /PRNewswire/ --  Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Monday, May 3, 2021 at 4:30 p.m. Eastern Time to discuss financial and operating resul...

Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare Conference News provided by Share this article Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that Panna Sharma, President and CEO of Lantern Pharma, will participate in the 20 th Annual Needham Healthcare Conference, to be held virtually on April 1...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, today announced a collaboration with Johns Hopkins Pediatric Oncology Division of The Sidney Kimmel Comprehensive Cancer Center and Dr. Eric Raabe, M.D., Ph.D. focused on Lanterns drug candidate LP-184 in the area of brain tumors, and specifically in Atypical Rhabdoid Tumors ("ATRT"), an u...

Share this article Share this article DALLAS, March 17, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that it has filed seven patent applications globally on a novel DNA-damaging agent with anticancer properties. These patent applications include claims directed to a newly synthesized compound with prom...

Share this article Share this article DALLAS, Dec. 17, 2020 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Kennedy Krieger Institute. The collaboratio...

Share this article DALLAS, Dec. 15, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ:  LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. LP-184 is being targeted for t...